You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lenograstim

Showing 26 - 50 of 368
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Poor Graft Function Trial (Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist)

Not yet recruiting
  • Poor Graft Function
  • (no location specified)
Jun 8, 2023

Acute Myeloid Leukemia Trial in Nanjing (Venclexta 100 MG Oral Tablet)

Recruiting
  • Acute Myeloid Leukemia
  • Venclexta 100 MG Oral Tablet
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Jun 11, 2023

Leukemia, Acute Myeloid (AML) Trial (Clifutinib, LoDAC, Azacitidine)

Not yet recruiting
  • Leukemia, Acute Myeloid (AML)
  • (no location specified)
Oct 16, 2022

Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Trial in Guangzhou (Granulocyte

Recruiting
  • Myelodysplastic Syndrome
  • +2 more
  • Granulocyte Colony-Stimulating Factor(G-CSF)
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Jul 11, 2022

Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Trial in

Recruiting
  • Secondary Acute Myeloid Leukemia Evolving From MDS
  • +2 more
  • Granulocyte Colony-Stimulating Factor(G-CSF)
  • +4 more
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Jul 5, 2022

Alcoholic Hepatitis Trial in Chuncheon (G-CSF (Filgrastim injection), steroid, )

Terminated
  • Alcoholic Hepatitis
  • G-CSF (Filgrastim injection)
  • +2 more
  • Chuncheon, Korea, Republic of
    Chuncheon Sacred Heart hospital
Aug 4, 2022

Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)

Not yet recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Boston, Massachusetts
  • +1 more
Mar 31, 2023

Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level

Not yet recruiting
  • Relapsed Adult AML
  • Refractory AML
  • Navitoclax Dose Level -1
  • +10 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023

Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • +11 more
  • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 24, 2022

Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
  • Best-Available Therapy(BAT) Regimen
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 10, 2023

Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma Trial in Bethesda, Cleveland (biological,

Not yet recruiting
  • Glioblastoma Multiforme
  • +3 more
  • P140K-MGMT
  • +5 more
  • Bethesda, Maryland
  • +1 more
Jul 4, 2022

HIV Trial in Los Angeles, Aurora (Filgrastim)

Completed
  • HIV Infections
  • Los Angeles, California
  • +1 more
Oct 28, 2021

Acute Myeloid Leukemia Trial in Shenyang (rhTPO, Decitabine)

Recruiting
  • Acute Myeloid Leukemia
  • Shenyang, Liaoning, China
    ShengJing Hospital of China Medical University
May 16, 2022

Neuroblastoma Trial in Minneapolis (drug, biological, radiation)

Recruiting
  • Neuroblastoma
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Apr 11, 2022

Healthy Trial in United States (Filgrastim)

Recruiting
  • Healthy
  • Duarte, California
  • +19 more
Mar 7, 2022

Multiple Myeloma Trial in Worldwide (BL-8040 1.25mg/kg + G-CSF, Placebo +G-CSF)

Active, not recruiting
  • Multiple Myeloma
  • BL-8040 1.25mg/kg + G-CSF
  • Placebo +G-CSF
  • Los Angeles, California
  • +17 more
Jun 14, 2022

Relapsed Follicular Lymphoma Trial in Italy (ZEVALIN, BEAM)

Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Genova, GE, Italy
  • +37 more
Dec 22, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Pediatric Cancer Trial in Guangzhou (pegylated recombinant human granulocyte-colony stimulating factor)

Recruiting
  • Pediatric Cancer
  • pegylated recombinant human granulocyte-colony stimulating factor
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center,
Aug 27, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (procedure, drug, biological)

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Trial in Seattle (procedure, drug, biological, radiation)

Recruiting
  • Acute Leukemia
  • +18 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 26, 2022

Early-stage Breast Cancer Trial in Ottawa (Granulocyte Colony-Stimulating Factor (G-CSF), Omission of Granulocyte

Not yet recruiting
  • Early-stage Breast Cancer
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
  • Ottawa, Ontario, Canada
    The Ottawa Hospital Cancer Centre
Feb 22, 2023

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Basiliximab, Carmustine, Cytarabine)

Recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Basiliximab
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Jun 16, 2022

Triple-Negative Breast Cancer Trial in Worldwide (Tiragolumab, Atezolizumab, Nab-paclitaxel)

Active, not recruiting
  • Triple-Negative Breast Cancer
  • Birmingham, Alabama
  • +23 more
Jan 19, 2023

Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Trial in Chicago (Carboplatin,

Recruiting
  • Human Papilloma Virus
  • +4 more
  • Chicago, Illinois
    University Of Chicago Medicine Comprehensive Cancer Center
Jun 3, 2022